Psoriatic arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many. Psoriatic arthritis is associated with a number of sleep problems, including…
The last day was jammed with important reports and research including the late breaking abstracts.
What imaging modality is best in GCA?
Dutch study: n=42
?GCA got all three of USS,…
A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized.
Opioid use can…
2 years 1 month ago
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
2 years 1 month ago
Pain in #psoriaticarthritis might not be all inflammatory..
In this study presented by Dr F Sunzini:
👉PsA pts w/⬆️FM scores had⬆️functional brain connectivity bet mid-post IC & thalamus, phgyrus & PFC
..so consider nociplastic pain too & adjust mgt
#ACR22 @RheumNow ABST#2256 https://t.co/suCAvx0pD5
2 years 1 month ago
BE OPTIMAL Study - Bimekizumab (IL-17A and IL-17F inhibitor) for treatment of PsA.
Similar ACR 50 (~50%) response rates of Bimekizumab, adalimumab, and placebo (switched to BKZ at wk 16).
~60% PASI100 in BKZ
#ACRBest Abs#L02 @RheumNow #ACR22 https://t.co/W2B2kyju9F
2 years 1 month ago
Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcomes sustained. No joint difference to ADA, skin slightly better @RheumNow #ACR22 Abstr#L02 https://t.co/RjCV8Hb3HR https://t.co/a0NQFyFZlt
Poster Hall